Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04FNR
|
|||
| Former ID |
DIB011417
|
|||
| Drug Name |
Mitumomab
|
|||
| Synonyms |
LuVax; MelVax; BEC-2; EMD-60205; IMC-BEC2; Antimelanoma antibody, ImClone/Merck KGaA; Antimetastatic agents, ImClone/Merck KGaA; Melanoma vaccine, ImClone/Merck KGaA; GD3 ganglioside (vaccine 1), Memorial Sloan-Kettering
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 3 | [1], [2] | |
| Company |
Memorial Sloan-Kettering Cancer Center
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7981). | |||
| REF 2 | ClinicalTrials.gov (NCT00037713) Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.